Ovarian rejuvenation with dehydroepiandrostenedione prior to a modified natural in vitro fertilization cycle: A new hope in premature ovarian insufficiency

Patients with primary ovarian insufficiency (POI) are classically oriented to egg donation due to the lack of currently available efficient treatments. In response to this shortcoming, modified natural in vitro fertilization cycle (mnIVF) combined with dehydroepiandrostenedione (DHEA) neoadjuvant treatment is an original therapeutic tool at our disposal. A 33-year-old patient with idiopathic POI was prescribed DHEA neoadjuvant treatment. She rapidly recovered her menstrual cycle and after 3 months of DHEA, basal follicle-stimulating hormone has decreased drastically. Then, a mnIVF was performed. The patient got pregnant and gave birth to a healthy girl. She became pregnant a second time under DHEA only. Coupled with DHEA neoadjuvant treatment, a mnIVF could be a useful therapeutic tool for extremely poor prognosis patients with POI.